Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 in Squamous Cell Lung Cancer with NSD3 Amplification
NCT05607108Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2022
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZEN3694 in squamous cell carcinoma of the lung (LSCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2022; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT05607108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607108.